SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) today announced that Dr. V. Wee Yong, of the Hotchkiss Brain Institute from the University of Calgary, will be presenting on behalf of SCT at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis ("ECTRIMS") which is being held in Dusseldorf, Germany, September 9-12, 2009.

Dr. V. Wee Yong's presentation will discuss the safety and efficacy of prolactin in the animal model of multiple sclerosis ("MS"), experimental autoimmune encephalomyelitis. The result of the work Dr. Yong and his team have done, has led to the design of a clinical trial in MS with Dr. Yong's colleagues at the University of Calgary, specifically Drs. Luanne Metz and Fiona Costello of the MS Clinic at the Foothills Medical Centre in Calgary, Alberta, and SCT.

Dr. Alan Moore, President and CEO of SCT, commented as follows:

"We are excited that Dr. Yong will be presenting at this international thought-leading MS conference as his work is clearly at the forefront for potential MS treatments. We look forward to initiating a clinical trial using prolactin to treat MS by the end of this year."

About the 25th Congress of the ECTRIMS (http://www.ectrims.eu/): ECTRIMS congresses have, over the years, evolved into the largest and most important annual international meeting dedicated to multiple sclerosis. These meetings bring together leading international experts in MS research, both scientists and clinicians, to share and discuss recent advances in this fast moving field. Clearly, the ultimate goal of all these efforts is to combat and eventually cure this disabling disease that affects some two million individuals throughout the world.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President and CEO (403) 245-5495 ext.224 amoore@stemcellthera.com Stem Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations (403) 245-5495 ext. 221 crampton@stemcellthera.com www.stemcellthera.com